Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Open accessThe DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western countries. Despite the high prevalence of NAFLD, the underlying biology of the disease progression is not clear, and there are no approved drugs to treat non-alcoholic steatohepatitis (NASH), the most advanced form of the disease. Thus, there is an urgent need for developing advanced in vitro human cellular systems to study disease mechanisms and drug responses. We attempted to create an organoid system genetically predisposed to NAFLD and to induce steatosis and fibrosis in it by adding free fatty acids. We used multilineage 3D spheroids composed by hepatocytes (HepG2) and hepatic stellate cells (LX-2) with a physiological ratio (24:1). HepG2 and LX-2 cells are homozygotes for the PNPLA3 I148M sequence variant, the strongest genetic determinant of NAFLD. We demonstrate that hepatic stellate cells facilitate the compactness of 3D spheroids. Then, we show that the spheroids develop accumulations of fat and collagen upon exposure to free fatty acids. Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs that are in clinical trials for the treatment of NASH. In conclusion, we have established a simple, easy to handle, in vitro model of genetically induced NAFLD consisting of multilineage 3D spheroids. This tool may be used to understand molecular mechanisms involved in the early stages of fibrogenesis induced by lipid accumulation. Moreover, it may be used to identify new compounds to treat NASH using high-throughput drug screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MASLD modeling using co-cultures aims to reproduce the tissue microenvironment of the liver, including intercellular interactions between hepatocytes and non-parenchymal cells (stellate, immune), which is a key factor in the progression from steatosis to steatohepatitis and fibrosis [132,133,134].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more complex systems (3D cultures, co-cultures), lower FFA concentrations (10–500 μM) are required [131,132,133,134], which brings conditions closer to physiological ones and reduces the risk of non-specific cytotoxicity.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For genetic studies of PNPLA3-dependent mechanisms, HepG2 + LX-2 3D spheroids [132] utilizing endogenous PNPLA3 I148M homozygosity serve as a unique platform.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
In the citing paper
“Co-culturing cells using conventional 2D methods or in 3D spheroids allows for functional characterisation of these interactions,14 but is hampered by the poor reproduction of the environment that drives NASH in vivo, with investigations often limited to 2 subpopulations rather than the multicellular environment.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 1×
“NAFLD encompasses a wide spectrum of pathologic conditions, including hepatic steatosis and non-alcoholic steatohepatitis (NASH), which can further progress to fibrosis, cirrhosis and hepatocellular carcinoma [2].”
BackgroundMechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 2×
“We found an increase in collagen levels after fatty acids treatment and as expected after treatment with TGF-β [48–50] the most potent fibrogenic cytokine [20].”
BackgroundHepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“However, after liver injury HSCs transdifferentiate and start producing extracellular matrix (ECM) proteins [17,19,21,22].”
BackgroundThe third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817 · cited 1×
“For instance, 3D cell cultures represent more closely the heterogeneous cell–cell interactions and offer a more similar micro-environment to the in vivo situation with respect to cell shape, adhesion, behavior, topology, and morphology [14].”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 1×
“Of note, clinical studies show how severe fibrosis is the best predictor of mortality in patients with NAFLD [16].”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942 · cited 1×
“TGF-β is critical for the activation of fibrogenic myofibroblasts, which in response to injury upregulate α-smooth muscle actin (α-SMA) and secrete extracellular matrix proteins, mostly collagen Type I [38,39].”
BackgroundFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834 · cited 1×
“This need has led to generation of more complex 3D in vitro models that have generated great attention [13].”
Background
Cited by
Items 101–157 of 157
NAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differences
Pérez-Luz, S., Matamala, N., Gómez‐Mariano, G., Janciauskiene, S. M., & Martínez–Delgado, B. (2023) · Biomedicines · doi:10.3390/biomedicines11071961 · Cited by 3
Mansouri, M., Lamichhane, A., Das, D., Aucejo, F., Tavana, H., & Leipzig, N. D. (2023) · Advanced Biology · doi:10.1002/adbi.202300386 · Cited by 3
Mouse Models for the Study of Liver Fibrosis Regression In Vivo and Ex Vivo
Schönke, M., & Rensen, P. C. N. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00212 · Cited by 13
Qin, C., Wu, H., Liao, P., Yan, W., Shi, X., Xie, J., Liu, S., Chen, S., Cao, X., Zhou, Y., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04865-7 · Cited by 3
“Alternatively, these hepatocytes are enzymatically dissociated into single-cell suspensions and cultured under low-adhesion conditions to spontaneously form non-structured hepatocyte aggregates [16].”
Tang, D., Yang, J., Shi, X., Gu, X., & Zhao, L. (2026) · Biology Direct · doi:10.1186/s13062-026-00783-7 · Cited by 3
“TGR5 inhibitor co-culture group (SBI-115 + LX-2): TDCA (500 µM) + SBI-115 (10 µM)-treated HiBECs + LX-2 cells [21].”
Hepatic Models in Precision Medicine: An African Perspective on Pharmacovigilance
Hurrell, T., Naidoo, J., & Scholefield, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.864725 · Cited by 3
Asadollahi, N., Hajari, M. A., Choshali, M. A., Ajoudanian, M., Ziai, S. A., Vosough, M., & Piryaei, A. (2024) · EXCLI journal · doi:10.17179/excli2023-6878 · Cited by 8
Wani, S. I., Mir, T. A., Nakamura, M. M., Tsuchiya, T., Alzhrani, A., Iwanaga, S., Arai, K., Alshehri, E. A., Shamma, T., Obeid, D. A., et al. (2024) · Bioprinting · doi:10.1016/j.bprint.2024.e00355 · Cited by 3
Maurotti, S., Scopacasa, B., Scionti, F., Pujia, R., Frosina, M., Mirarchi, A., Geirola, N., Mare, R., Montalcini, T., Candeloro, P., et al. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112679 · Cited by 2
Kawahara, M., Miyazaki, K., Anada, T., Kobayashi, S., & Tanaka, M. (2025) · ACS Omega · doi:10.1021/acsomega.5c09030 · Cited by 2
Dynamic modelling of liver–bone axis: A microphysiological approach to hepatic osteodystrophy
Gupta, P., Mehrotra, S., Aspera-Werz, R. H., Mairal, A., Pandit, A. H., Nussler, A. K., & Kumar, A. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.12.011 · Cited by 2
“Previous studies have shown that the inclusion of LX2 and HUVEC cells also enhances the compactness and structural integrity of liver spheroids, hence promoting cellular cohesion [57].”
Tan, S., Cai, Y.-H., Wang, W. C., Ma, L., Zuo, X., Xu, T., Liu, H.-X., Zhang, Y., Gao, H., Liang, G., et al. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.108192 · Cited by 2
Set up of a human 3D liver multicellular model for chemical high-throughput toxic hazard assessment
Recoules, C., & Audebert, M. (2025) · NAM journal. · doi:10.1016/j.namjnl.2025.100075 · Cited by 3
Han, Y.-Q., Xu, Y., Xiang, Z., Xu, Q.-F., Gao, F., Yan, M.-N., & Wu, J. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.01.008 · Cited by 2
Miranda, M. R., Aquino, G., Ciaglia, T., Amodio, G., Basilicata, M. G., Tecce, M. F., Vestuto, V., Campiglia, P., Manfra, M., & Pepe, G. (2026) · Journal of Food Biochemistry · doi:10.1155/jfbc/3782560 · Cited by 2
Wu, Y., Wang, Y., Zhang, W., Yuan, L.-L., & Chen, Y. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05080-8 · Cited by 2
“While varying co-culture ratios appear to have minimal impact on spheroid formation, it may lead to different maturation phenotypes [141].”
Shi, J., Xu, W., Yang, T., Bayijuma, A., Huang, Y., & Zhou, Y. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114708 · Cited by 2
Rola samorzadu terytorialnego w rozwoju lokalnym
Parysek, J. J. (1995) · Studia. Polska Akademia Nauk. Komitet Przestrzennego Zagospodarowania Kraju · Cited by 18
Ortiz, E., Thway, K. H., Ortíz-Soto, G., Yao, P., & Kelber, J. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.21.634082 · Cited by 2
Wu, C. T., Moncsek, A., & Mertens, J. C. (2025) · Liver International · doi:10.1111/liv.70352 · Cited by 1
“HepG2 cells are widely used in in vitro liver models due to their metabolic activity, stability, and accessibility, though they do not fully represent primary hepatocytes [19, 33–39].”
Comparative Evaluation of HepG2 Spheroid Generation Methods for Toxicology
Planchak, S., Moyers, A. H., Chen, Y., Lockwood, O., & Tripathi, A. (2026) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-026-00894-1 · Cited by 1
Bogovic, N., Drießlein, M., Keller, M., Schlitt, H. J., Geissler, E. K., Schneider, L., Kreiner, P., Junger, H. H. G., & Eggenhofer, E. (2026) · Biology Open · doi:10.1242/bio.062552 · Cited by 1
“…in other 3D models: Mukherjee et al. (2019) described bridging fibrosis-like collagen deposition after palmitate treatment (Mukherjee et al., 2019), Pingitore et al. (2019) demonstrated collagen induction in PNPLA3-mutant spheroids (Pingitore et al., 2019), and Ströbel et al. (2021) reported…”
InfluentialКотлярова, А. А., & Kotlyarov, S. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104453 · Cited by 1
Kim, H. M., Oh, E. J., Kwak, S., Han, S. O., & Chung, H. Y. (2026) · Cells · doi:10.3390/cells15110969 · Cited by 1
“These limitations further highlight the need for human-specific models capable of bridging the gap between basic research and clinical application [32].”
Wölfle, U., Haarhaus, B., Ditengou, F. A., Weiskirchen, R., Rusignuolo, G., Boettler, T., & Schempp, C. M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119478 · Cited by 1
Helmer, A., Kern, J., Prohaska, P., Sadick, H., Kramer, B., Zaubitzer, L., Schell, A., ROTTER, N., & Häussler, D. (2026) · In Vivo · doi:10.21873/invivo.14417 · Cited by 1
Translational tissue engineering
Nair, A., Nadine, S., Ahadian, S., Mano, J. F., Tanideh, N., & Thankam, F. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824064-9.00023-x · Cited by 1
Advances and applications in liver organoid technology
Lin, L., Miao, L. E. I., JiaMan, L. I. N., & Hu, W. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0283 · Cited by 2
Chand, V. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.249238 · Cited by 1
Sharma, P. K., Kumar, L., Baghel, A., Jana, P., Dhar, K., Bansal, R., Goswami, Y., Kumari, A., Yadav, R., Shalimar, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.25.701562 · Cited by 1
“The effects of I3A and MCC-950 were analysed for inhibition of palmitic acid (PA) induced fibrosis in the 3D spheroid model using a co-culture of Hep-G2 and LX2 cells [33-34].”
Knockout of STE20-type kinase TAOK3 does not attenuate diet-induced NAFLD development in mice
Xia, Y., Andersson, E., Caputo, M., Cansby, E., Sedda, F., Font‐Gironès, F., Ruud, J., Kurhe, Y., Hallberg, B., Marschall, H., et al. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00738-y
“…hepatocytes (M00995-P, BioIVT, Westbury, NY), HepG2 (human hepatoblastoma-derived cells; HB-8065, LGC Standards, Teddington, UK), and Huh7 (human HCC cells; JCRB0403, JCRB Cell Bank, Tokyo, Japan) were cultured as previously described (Xia et al. 2021; Pingitore et al. 2019; Mancina et al. 2022).”
Self-citationOrtiz, E., Thway, K. H., Ortíz-Soto, G., Yao, P., & Kelber, J. A. (2025) · Journal of Visualized Experiments · doi:10.3791/67902
Xia, Y., Andersson, E., Caputo, M., Cansby, E., Sedda, F., Font‐Gironès, F., Ruud, J., Kurhe, Y., Hallberg, B., Marschall, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24416291
Self-citationXia, Y., Andersson, E., Caputo, M., Cansby, E., Sedda, F., Font‐Gironès, F., Ruud, J., Kurhe, Y., Hallberg, B., Marschall, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24416184
Self-citationΣυστημική μοντελοποίηση muti-omics δεδομένων για εύρεση μηχανισμών ανθρώπινων ασθενειών
Zareifi, D.-S. (2022) · DSpace - NTUA (National Technical University of Athens) · doi:10.26240/heal.ntua.22425
Lo, P. C. K. (2022) · Nottingham ePrints (University of Nottingham)
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Böttcher, N., Krumm, P., Huchzermeier, R., Berschkeit, L., Vollmer, J., Dick, J., Pufe, T., & Fragoulis, A. (2026) · Bioengineering · doi:10.3390/bioengineering13030336
Mise au point et développement de modèles hépatiques complexes par bio-impression 3D
Cuvellier, M. (2020) · theses.fr (ABES) · doi:10.70675/b6c577cdzcaffz460az8214z9681de8f3941
Leveraging the replication stress response to optimize hepatocarcinoma therapy
Fang, J. (2024) · theses.fr (ABES) · doi:10.70675/e829496azb11ez4563zb5c8z74b7e8e8ff61
Morisseau, L. (2023) · theses.fr (ABES) · doi:10.70675/cfa5953ez697dz47bez9768zde0845d5a7b8 · Cited by 1
Aina, K. O. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102616
Vascularization in Biofabrication: Innovative Strategies for Advanced Tissue Models
Kulicke, Y., Schmid, R., Promny, T., Karimi, T., Sandor, E., Wedler, L., Sörgel, C. A., Arkudas, A., Kengelbach‐Weigand, A., & Horch, R. E. (2026) · Cells · doi:10.3390/cells15141245
“To introduce components of the TME, other cell types such as fibroblasts, pancreatic stellate cells or immune cells may also be added [246–248].”
Immunomodulatory efficacy of culture condition-dependent modulation of mesenchymal stem cells
Sun, Q., Zhang, X., Dong, H., Mi, C., Geng, S., Li, Q., Zhang, J., Wang, X., & Wang, T. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05169-0
“It has interactions between cells, as well as between cells and extracellular matrix, and can better simulate the physiological micro-environment of the human body [68–70].”
Human placenta extract declines fat deposition in an in vitro novel 3D MASLD model
Taheri, P., Majidi, F., Nouri, K., Nouri, M., Zarrabi, M., Rismani, E., Piryaei, A., & Vosough, M. (2026) · In vitro models · doi:10.1007/s44164-026-00142-w
Song, M., Fang, Y., Gong, X., Wang, J., Han, Y., Wang, K., Yu, X., & Tang, J. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04878-1
“In vitro 3D fibrosis models were mainly prepared using the method previously reported by Pingitore et al. [31].”
3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening
Alikhani, H. K., Majidi, F., Ghasemzad, M., Shpichka, A. I., Nestorova, A., Hendi, Z., Rismani, E., Kuznetsova, D. S., Timashev, P., Vosough, M., et al. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70306
“However, Vitamin E and Obeticholic acid did not show any effect on the prevention of these fibrotic parameters [209].”
Experimental Models for Drug Repurposing in Viral Hepatitis
Talukdar, A., & Devi, A. (2026) · Wiley eBooks · doi:10.1002/9781394466573.ch15
Ghasemzadeh‐Hasankolaei, M., McCormick, S., Magne, L., Vrana, N. E., & Ghaemmaghami, A. M. (2026) · Toxicology · doi:10.1016/j.tox.2026.154575
Xue, H.-Y., Ren, T., Pan, Q., & Fan, J.-G. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.123934
Ramos, J. M. O., VASCONCELLOS, J. G., do Nascimento, N. B., de Sousa, A. C., Giehl, M. L., Fischer, B. S., Ferreira, J. D. S., de Oliveira, J., Trindade, V. M. T., & Guma, F. T. C. R. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12715-9
“By enhancing compact - ness and possibly contributing ECM components, LX-2 cells modulate the physical and biochemical environment, supporting cell survival [52].”
Mirarchi, A., Galluccio, A., Mare, R., Maurotti, S., Scionti, F., Noto, F. R., Mirabello, L. C., Rago, M., Rotundo, L., Peta, A., et al. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.110105
Bushra, A., Oelze, E., Locke, T., Jayne, D., Han, X., Fan, T. M., & Irudayaraj, J. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00127
A live-cell medium-throughput assay for quantifying lipid accumulation in hepatocytes
Ko, M. C. D., Nowell, C. J., Turpin-Nolan, S. M., & Flynn, B. L. (2026) · Methods · doi:10.1016/j.ymeth.2026.10.006
Metadata
- Authors
- Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S.
- Affiliations
- University of Gothenburg (SE)
- AstraZeneca (Sweden) (SE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Romeo, Stefano
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-02
- Volume
- 20
- Issue
- 7
- Pages
- 1629
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6480107
- OpenAlex
- W2935565749
- Cited by
- 152
- References
- 64
- Citations by year
- 2026: 28 · 2025: 22 · 2024: 19 · 2023: 23 · 2022: 22 · 2021: 16 · 2020: 19 · 2019: 2
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Vetenskapsrådet (2016-01527)
- Hjärt-Lungfonden (20120533)
- the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (SU 2018-04276)
- Novonordisk Foundation Grant for Excellence in Endocrinology (Excellence Project, 9321-430)
- Swedish Diabetes Foundation (DIA 2017-205)
- Research grant from AstraZeneca (Echo Project, 10033852)
- Wallenberg Academy Fellows from the Knut and Alice Wallenberg Foundation (KAW 2017.0203)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, liver fibrosis, multicellular spheroids, organoids, PNPLA3 I148M, HepG2 cells, LX-2 cells, hepatic stellate cells, hepatocytes, free fatty acids, liraglutide, elafibranor, in vitro disease model, drug screening
- MeSH terms
- Liraglutide, Apolipoproteins B, Fatty Acids, Humans, Liver Cirrhosis, Models, Biological, Propionates, Spheroids, Cellular, Coculture Techniques, Cell Lineage, Collagen Type I, Chalcones, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.